These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 28214929)

  • 21. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
    Guha P; Gardell J; Darpolor J; Cunetta M; Lima M; Miller G; Espat NJ; Junghans RP; Katz SC
    Oncogene; 2019 Jan; 38(4):533-548. PubMed ID: 30158673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cells.
    Herrmann A; Kortylewski M; Kujawski M; Zhang C; Reckamp K; Armstrong B; Wang L; Kowolik C; Deng J; Figlin R; Yu H
    Cancer Res; 2010 Oct; 70(19):7455-64. PubMed ID: 20841481
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity.
    Merrell MA; Ilvesaro JM; Lehtonen N; Sorsa T; Gehrs B; Rosenthal E; Chen D; Shackley B; Harris KW; Selander KS
    Mol Cancer Res; 2006 Jul; 4(7):437-47. PubMed ID: 16849519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. IL-17 inhibits the accumulation of myeloid-derived suppressor cells in breast cancer via activating STAT3.
    Ma M; Huang W; Kong D
    Int Immunopharmacol; 2018 Jun; 59():148-156. PubMed ID: 29655056
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy.
    Chesney JA; Mitchell RA; Yaddanapudi K
    J Leukoc Biol; 2017 Sep; 102(3):727-740. PubMed ID: 28546500
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immune mechanisms and therapeutic potential of CpG oligodeoxynucleotides.
    Wilson HL; Dar A; Napper SK; Marianela Lopez A; Babiuk LA; Mutwiri GK
    Int Rev Immunol; 2006; 25(3-4):183-213. PubMed ID: 16818371
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STAT3: a target to enhance antitumor immune response.
    Lee H; Pal SK; Reckamp K; Figlin RA; Yu H
    Curr Top Microbiol Immunol; 2011; 344():41-59. PubMed ID: 20517723
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastases.
    Ghosh CC; Cournoyer L; Liu Y; Ballarin A; Layman IB; LaPorte J; Morrissey M; Fraser K; Perati S; Cox BF; Yakirevich E; Treaba DO; Murtha TD; Guha P; Katz SC; Davar D
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39038918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of checkpoint molecules on myeloid-derived suppressor cells.
    Ballbach M; Dannert A; Singh A; Siegmund DM; Handgretinger R; Piali L; Rieber N; Hartl D
    Immunol Lett; 2017 Dec; 192():1-6. PubMed ID: 28987474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myeloid STAT3 Promotes Lung Tumorigenesis by Transforming Tumor Immunosurveillance into Tumor-Promoting Inflammation.
    Zhou J; Qu Z; Sun F; Han L; Li L; Yan S; Stabile LP; Chen LF; Siegfried JM; Xiao G
    Cancer Immunol Res; 2017 Mar; 5(3):257-268. PubMed ID: 28108629
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.
    Stahl M; Gedrich R; Peck R; LaVallee T; Eder JP
    Immunotherapy; 2016 Jun; 8(7):767-74. PubMed ID: 27349976
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myeloid-derived suppressor cells: Implication in myeloid malignancies and immunotherapy.
    Kapor S; Radojković M; Santibanez JF
    Acta Histochem; 2024 Oct; 126(5-7):152183. PubMed ID: 39029317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
    Senn JJ; Burel S; Henry SP
    J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cytidine-phosphate-guanosine oligonucleotides induce interleukin-8 production through activation of TLR9, MyD88, NF-κB, and ERK pathways in odontoblast cells.
    He W; Zhang Y; Zhang J; Yu Q; Wang P; Wang Z; Smith AJ
    J Endod; 2012 Jun; 38(6):780-5. PubMed ID: 22595112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oligo-PROTAC strategy for cell-selective and targeted degradation of activated STAT3.
    Hall J; Zhang Z; Bhattacharya S; Wang D; Alcantara M; Liang Y; Swiderski P; Forman S; Kwak L; Vaidehi N; Kortylewski M
    Mol Ther Nucleic Acids; 2024 Mar; 35(1):102137. PubMed ID: 38384444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ultrasound Targeted Microbubble Destruction-Mediated Delivery of a Transcription Factor Decoy Inhibits STAT3 Signaling and Tumor Growth.
    Kopechek JA; Carson AR; McTiernan CF; Chen X; Hasjim B; Lavery L; Sen M; Grandis JR; Villanueva FS
    Theranostics; 2015; 5(12):1378-87. PubMed ID: 26681983
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression.
    Wang SH; Lu QY; Guo YH; Song YY; Liu PJ; Wang YC
    Eur J Cancer; 2016 Nov; 68():90-105. PubMed ID: 27728841
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.
    Chuang YC; Tseng JC; Huang LR; Huang CM; Huang CF; Chuang TH
    Front Immunol; 2020; 11():1075. PubMed ID: 32547560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A STAT3 decoy lures AML out of hiding.
    Redell MS
    Blood; 2016 Mar; 127(13):1628-9. PubMed ID: 27034418
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA-inorganic hybrid nanovaccine for cancer immunotherapy.
    Zhu G; Liu Y; Yang X; Kim YH; Zhang H; Jia R; Liao HS; Jin A; Lin J; Aronova M; Leapman R; Nie Z; Niu G; Chen X
    Nanoscale; 2016 Mar; 8(12):6684-92. PubMed ID: 26947116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.